Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIOP 2: Post-Operative LMWH Bridging Therapy
NCT00432796Phase 3Unknown
- Start
- Dec 2006
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in arterial thromboembolism comparing Dalteparin with Placebo (2 arms). Primary endpoint: Frequency of episodes of major thromboembolism at 90 days. Status: unknown.
02
Drugs
dalteparin
03
Conditions
arterial thromboembolism
Beyond the preview
Go deeper on NCT00432796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432796.